Workflow
凯莱英
icon
Search documents
小摩增持凯莱英9400股 每股作价约87.56港元
Zhi Tong Cai Jing· 2026-02-13 12:52
香港联交所最新资料显示,2月10日,小摩增持凯莱英(002821)(06821)9400股,每股作价87.5591港 元,总金额约为82.31万港元。增持后最新持股数目约为167.41万股,最新持股比例为6.01%。 ...
小摩增持凯莱英(06821)9400股 每股作价约87.56港元
智通财经网· 2026-02-13 12:47
智通财经APP获悉,香港联交所最新资料显示,2月10日,小摩增持凯莱英(06821)9400股,每股作价 87.5591港元,总金额约为82.31万港元。增持后最新持股数目约为167.41万股,最新持股比例为6.01%。 ...
葛兰管理规模缩水近70%,中欧是否仍在“顶流依赖”?
3 6 Ke· 2026-02-12 07:51
2025年四季度公募基金成绩单已出炉,"医药女神" 葛兰又一次站在了风口上。 葛兰能成为千亿顶流,一半是实力加持,一半是踩中了行业风口。 而中欧基金则借着她的东风,快速坐稳了主动权益赛道的头部位置,两人的崛起是一场互相成就。 事实上,和其他基金经理比,葛兰的专业底色足够硬。 她是国内医疗主题基金里少有的美国生物医学工程博士,懂医药研发、懂行业逻辑,这也是她能精准抓 住医药赛道机遇的关键。 数据显示,截至2025年年末,葛兰手里管的基金总规模缩减到了353.89亿元,比三季度少了81.55亿元; 而距离2021年千亿巅峰,已跌去750亿元,缩水幅度达68%。 此前,葛兰凭着年化超30%的收益封神,一举成为中欧基金顶流,被基民广泛熟知;如今,随着业绩持 续回调、规模不断缩水,质疑声越来越多。 当顶流的光环褪去,靠明星基金经理撑起的公募巨头,该怎么跳出 "一人衰、公司忧" 的怪圈?这不仅 是中欧的难题,更是整个公募行业都要面对的考验。 基金规模缩水近七成 2016到2021年,是葛兰的黄金五年,也是中欧基金借势起飞的五年。 那时候医药板块迎来牛市,尤其是创新药、医药研发生产外包(CXO)赛道,涨得一飞冲天,葛兰的 ...
康龙化成股东减持与H股配售完成,2025年业绩预告显示主营业务增长
Jing Ji Guan Cha Wang· 2026-02-12 05:37
Company Situation - The company completed a general authorization placement of 58.4408 million new H-shares in January 2026, raising approximately HKD 1.319 billion, with a placement price of HKD 22.82, reflecting an 8.5% discount to the previous closing price. The funds are intended for laboratory and production facility construction, debt repayment, and working capital supplementation, which may impact the equity structure and short-term liquidity [2] Performance and Operating Conditions - The company announced on January 13, 2026, that it expects total revenue for 2025 to be between RMB 13.872 billion and RMB 14.24 billion, representing a year-on-year growth of 13% to 16%. However, the net profit attributable to the parent company is expected to decline by 6% to 10% year-on-year, primarily due to a decrease in non-recurring gains and losses. The net profit excluding non-recurring items is projected to increase by 36% to 41%, indicating an enhancement in the profitability of the main business [3] Industry and Risk Analysis - The CXO industry is experiencing intensified competition, with domestic leaders such as WuXi AppTec and Kelun Pharmaceutical, as well as international companies like Lonza, accelerating their market presence. This competitive landscape may exert pressure on the company's market share and pricing strategies. The company needs to address these challenges through capacity release and strategic acquisitions, such as the acquisition of Wuxi Bai'ao in November 2025 [4]
天津经开区:从能源破局到百亿投建 传统园区的零碳转型样本
Xin Lang Cai Jing· 2026-02-10 23:13
Core Viewpoint - The Tianjin Economic and Technological Development Zone (TEDA) is advancing towards becoming a national-level zero-carbon park by 2030, focusing on transforming its existing industrial energy systems to achieve low-carbon goals while maintaining economic stability [1][2][3]. Group 1: Zero-Carbon Park Development - TEDA has been selected as one of the first national-level zero-carbon parks, with a construction plan to be completed by 2030 [1][2]. - The park will implement a five-year plan to guide the development of the zero-carbon park, emphasizing the need for a systematic energy supply-side transformation [4][5]. - The core indicator for the zero-carbon park is to achieve a carbon emission of no more than 0.2 tons per ton of standard coal consumed, alongside a clean energy consumption rate exceeding 50% [7][8]. Group 2: Energy System Transformation - The transformation will focus on upgrading the existing energy supply system rather than starting from scratch, which presents unique challenges due to the complexity of the current industrial ecosystem [3][6]. - The park plans to close existing coal-fired boilers to significantly reduce carbon emissions, which is a key strategy to meet the core indicator [5][6]. - Investment for the low-carbon transformation is projected to reach a scale of around 100 billion yuan, targeting the "source, network, load, and storage" aspects of the energy system [8][9]. Group 3: Corporate Participation and Support - Corporate engagement is crucial for the success of the zero-carbon park, with varying motivations among companies, such as compliance with international carbon regulations and customer demands for low-carbon supply chains [10][12]. - The park has established a management mechanism that combines incentives and constraints to encourage companies to meet energy-saving targets, with support for those exceeding their goals [12][13]. - Companies are encouraged to build energy management centers and connect to online monitoring systems to enhance energy efficiency and carbon management [12][13].
2月10日生物经济(970038)指数涨0.05%,成份股福瑞医科(300049)领涨
Sou Hu Cai Jing· 2026-02-10 10:25
Core Viewpoint - The Biotech Index (970038) closed at 2196.51 points, up 0.05%, with a trading volume of 15.75 billion yuan and a turnover rate of 1.32% [1] Group 1: Index Performance - On the day, 20 stocks in the Biotech Index rose, with Furuimei leading at a 4.45% increase, while 28 stocks fell, with Aimeike leading the decline at 2.87% [1] - The net outflow of main funds from the Biotech Index constituents totaled 327 million yuan, while retail funds saw a net inflow of 162 million yuan [1] Group 2: Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.73%, latest price of 190.36 yuan, and a market cap of 230.8 billion yuan [1] - Deep Technology (sz000021) with a weight of 5.05%, latest price of 28.69 yuan, and a market cap of 45.09 billion yuan [1] - Tigermed (sz300347) with a weight of 4.85%, latest price of 66.60 yuan, and a market cap of 57.34 billion yuan [1] - Other notable constituents include Changchun High-tech, Kanglong Chemical, and Yuyue Medical, all within the biotech sector [1] Group 3: Fund Flow Details - Detailed fund flow for selected stocks shows: - Kanglong Chemical (300759) had a main fund inflow of 10.6 million yuan, but retail funds saw a net outflow of 87.37 million yuan [2] - Furuimei (300049) experienced a main fund inflow of 63.48 million yuan, while retail funds had a net outflow of 64.28 million yuan [2] - Mindray Medical (300760) had a main fund inflow of 45.80 million yuan, with retail funds also experiencing a net outflow [2]
天津经开区:从能源破局到百亿投建,传统园区的零碳转型样本
Core Viewpoint - The Tianjin Economic and Technological Development Zone (TEDA) is advancing towards becoming a national-level zero-carbon park by 2030, focusing on transforming its existing industrial energy systems to achieve low-carbon goals while maintaining economic stability [1][2][3]. Group 1: Zero-Carbon Park Development - TEDA has been selected as one of the first national-level zero-carbon parks, with a construction plan to be completed by 2030 [1][3]. - The park will implement a five-year plan to guide the development of the zero-carbon park, emphasizing the need for a systematic energy supply-side transformation [4][5]. - The core indicator for the zero-carbon park is to achieve a carbon emission of no more than 0.2 tons per ton of standard coal consumed, alongside a clean energy consumption rate exceeding 50% [7][8]. Group 2: Energy System Transformation - The transformation will focus on upgrading the existing energy supply system rather than starting from scratch, which presents unique challenges due to the complexity of the current industrial ecosystem [2][3]. - The park plans to close existing coal-fired boilers to significantly reduce carbon emissions, which is a key strategy to meet the core indicator [5][7]. - Investment for the low-carbon transformation is projected to reach a scale of around 10 billion, targeting four core areas: source, network, load, and storage [8][9]. Group 3: Corporate Participation and Support - Corporate engagement is crucial for the success of the zero-carbon park, with varying motivations among companies, such as compliance with international carbon regulations and supply chain requirements [10][12]. - The park has established a closed-loop management mechanism that incentivizes companies to meet energy-saving targets, providing financial and policy support for successful projects [12][13]. - Companies are encouraged to build energy management centers and connect to online monitoring systems to enhance energy efficiency and carbon management [12][13].
港股收评:三大指数收涨,传媒板块集体走强
Market Performance - The Hang Seng Index closed up 0.58%, the Hang Seng Tech Index rose 0.62%, and the Hang Seng China Enterprises Index increased by 0.81% [1] - The optical communication sector led the gains, with Longi Fiber Optics rising by 8.8%, Dongfang Electric up over 7%, and Weichai Power increasing by 3.69% [1] Sector Highlights - The cultural media sector saw significant gains, with Digital Kingdom surging over 29%, Reading Group rising over 15%, and DaMai Entertainment and China Ruyi both increasing by over 5% [1] - Biopharmaceutical stocks strengthened, with WuXi AppTec rising over 4%, Rongchang Bio up 3.64%, and Kailai Ying increasing by 3.5% [2] Individual Stock Movements - Notable individual stock movements included Digital Kingdom with a rise of 29.31%, Mao Yi Chuang up 21.92%, and Wan Ka Yi Lian increasing by 20% [2] - The education sector experienced declines, with Dongfang Zhenxuan down over 9% and New Oriental-S falling over 4% [4] New Listings - Le Xin Outdoor debuted with a remarkable increase of 102.29%, closing at 24.78 HKD, and at one point, it surged over 130% during trading [4] AI and Technology Developments - The stock of Zhipu AI, referred to as the "first global large model stock," saw a peak increase of over 24%, with a two-day cumulative rise exceeding 56% [5] - The release of the AI video generation model Seedance 2.0 by ByteDance is expected to significantly reduce production costs and enhance efficiency in the AI drama and short drama sectors, potentially accelerating industry growth [7]
港股医药外包概念股震荡走强,昭衍新药、药明生物、维亚生物均涨超3%
Mei Ri Jing Ji Xin Wen· 2026-02-10 02:09
Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a strong rally on February 10, with several companies seeing significant stock price increases [1] - Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rose by over 3% [1] - Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) each saw their stock prices increase by more than 2.5% [1]
港股医药外包概念股震荡走强,昭衍新药(06127.HK)、药明生物(02269.HK)、维亚生物(01873.HK)均涨超3%,泰格医药(03347.H...
Jin Rong Jie· 2026-02-10 02:09
Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]